Gastrointestinal Carcinoid Tumor (NET): Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Gastrointestinal carcinoid tumors are now formally classified as well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) per the 2022 WHO Classification of Tumors. They arise from enterochromaffin cells of the gut mucosa and are the most common GI endocrine tumors, with an incidence of approximately 4 per 100,000. The small intestine (ileum) is the most common site (30%), followed by the rectum (18%), and appendix (16%). Appendiceal carcinoids are almost always discovered incidentally and are rarely malignant if under 2 cm. Tumors are graded by Ki-67 proliferative index: G1 (Ki-67 <3%), G2 (3–20%), G3 (>20%). Most GI carcinoids are G1 or G2 (well-differentiated) and grow slowly, leading to delayed diagnosis — often 5–7 years after symptom onset. Metastatic disease to the liver is present in ~25% of patients at diagnosis, particularly from midgut primaries. Despite metastases, median survival can exceed 5–10 years with modern treatments.

The precise etiology of sporadic GI NETs remains incompletely understood. Most arise sporadically without an identifiable hereditary cause. Multiple endocrine neoplasia type 1 (MEN1) syndrome — caused by germline MEN1 mutations — predisposes to gastric, duodenal, and pancreatic NETs. Gastric NETs (Type 1 and 2) arise from enterochromaffin-like (ECL) cells driven by hypergastrinemia: Type 1 occurs in autoimmune chronic atrophic gastritis (pernicious anemia), Type 2 in Zollinger-Ellison syndrome/MEN1, and Type 3 are sporadic and most aggressive. Risk factors for sporadic midgut NETs are poorly defined; male sex and older age (peak incidence 50–70 years) are associated factors. Somatic mutations in CDKN1B (p27), DAXX, and ATRX have been identified in GEP-NETs. There is no established dietary or environmental risk factor.

The majority of GI NETs are non-functional and present with symptoms of local tumor growth: crampy abdominal pain, intestinal obstruction (mesenteric fibrosis — a hallmark of midgut NETs), or rectal bleeding. Approximately 10% of midgut NETs cause carcinoid syndrome once hepatic metastases are present, as serotonin and other vasoactive peptides escape hepatic metabolism. Classic carcinoid syndrome comprises episodic flushing (90%), diarrhea (70%), bronchospasm (15%), and right-sided cardiac valvular disease (carcinoid heart disease, Hedinger syndrome). Flushing is often triggered by alcohol, exercise, or emotional stress. Carcinoid crisis — life-threatening hemodynamic instability — can be precipitated by surgery, biopsy, or anesthesia induction. Niacin deficiency (pellagra) may develop due to tryptophan diversion to serotonin synthesis. Appendiceal NETs are almost always asymptomatic, discovered incidentally during appendectomy.

Biochemical markers are the first-line screening tool. Chromogranin A (CgA) is the most sensitive general NET marker (sensitivity 60–100%, specificity 68–100%), though it is falsely elevated by proton pump inhibitor use. 24-hour urine 5-hydroxyindoleacetic acid (5-HIAA) is the gold standard for diagnosing carcinoid syndrome (sensitivity ~73%, specificity ~100%). Serum serotonin and plasma 5-HIAA are alternative quantification methods. Somatostatin receptor scintigraphy using Gallium-68 DOTATATE PET-CT (SSTR PET-CT) has largely replaced OctreoScan: it has sensitivity of 93% vs 52% for detecting primary and metastatic disease. CT chest/abdomen/pelvis and MRI liver define the extent of hepatic and lymph node involvement. Endoscopy (EGD, colonoscopy, capsule endoscopy) locates primary tumors. Echocardiography is required to evaluate right-sided cardiac valve disease in patients with carcinoid syndrome. Tumor grading requires Ki-67 immunostaining and mitotic count on biopsy.

Surgical resection is the definitive treatment for localized GI NETs. Small bowel NETs require segmental resection with regional mesenteric lymphadenectomy, as multi-focal tumors are found in 25–30% of cases. Appendiceal NETs under 2 cm are cured by appendectomy alone; those 2 cm or larger require right hemicolectomy. Rectal NETs under 1 cm are managed by endoscopic mucosal resection. For metastatic disease, the PROMID trial established octreotide LAR 30 mg monthly as standard antiproliferative therapy for midgut G1/G2 NETs; the CLARINET trial established lanreotide autogel 120 mg monthly for GEP-NETs. Peptide receptor radionuclide therapy (PRRT) with lutetium-177 DOTATATE (Lutathera) is the standard for progressive somatostatin receptor-positive NETs per NETTER-1 trial (progression-free survival: 65.2% at 20 months vs 10.8% with high-dose octreotide). Everolimus (mTOR inhibitor) and sunitinib improve PFS in progressive NETs. Cytoreductive surgery and liver-directed therapies (TACE, ablation, selective internal radiotherapy) are used for hepatic-dominant disease.

Prognosis for gastrointestinal NETs (carcinoid tumors) is generally favorable compared to other gastrointestinal malignancies, reflecting their well-differentiated and slow-growing nature. Localized appendiceal NETs under 2 cm and rectal NETs under 1 cm: 5-year OS approaches 100% after complete surgical resection. Small intestinal NETs with regional lymph node involvement: 5-year OS approximately 72-85%. Small intestinal NETs with hepatic metastases: 5-year OS approximately 45-65% with modern multimodality management; median OS often exceeds 5-10 years — dramatically superior to other stage IV gastrointestinal malignancies, reflecting the indolent biology. The NETTER-1 trial demonstrated that PRRT with 177Lu-DOTATATE extends 20-month PFS from 10.8% to 65.2% versus high-dose octreotide LAR in progressive midgut NETs. Grade 3 neuroendocrine carcinoma (poorly differentiated, Ki-67 greater than 20%): median OS approximately 11-13 months with platinum-etoposide chemotherapy. Gastric Type 3 NETs (sporadic, aggressive) behave similarly to gastric adenocarcinoma with poor prognosis. Without treatment, functioning NETs with carcinoid syndrome progress relentlessly, and carcinoid heart disease (Hedinger syndrome) causes progressive right heart failure significantly worsening prognosis. Key prognostic factors include WHO grade (Ki-67 index — the most important determinant), primary site and resectability, presence and extent of liver metastases, somatostatin receptor expression (positive predicts PRRT eligibility and response), and carcinoid heart disease severity. Long-term monitoring is essential given indolent growth behavior: chromogranin A and urine 5-HIAA every 3-6 months, 68Ga-DOTATATE PET-CT every 2-3 years or with biochemical progression, echocardiography annually for carcinoid syndrome patients, and CT or MRI every 6-12 months.

No specific strategies prevent sporadic GI carcinoid tumors. Patients with MEN1 syndrome require annual biochemical screening (CgA, gastrin, glucagon) from age 5 and regular cross-sectional imaging to detect pancreatic and duodenal NETs early per ENETS consensus guidelines. Type 1 gastric NETs are prevented by treating autoimmune gastritis; in selected cases, antrectomy to reduce hypergastrinemia leads to regression. H. pylori eradication reduces the gastric acid suppression that may contribute to ECL cell hyperplasia. Long-term PPI use does not increase NET incidence significantly despite elevating CgA. Genetic counselling and germline MEN1 testing are indicated for any patient with a GI NET before age 40 or with synchronous endocrine neoplasms.

Seek immediate evaluation if episodic flushing, watery diarrhea, bronchospasm, or right heart failure symptoms develop — these suggest carcinoid syndrome requiring urgent work-up and somatostatin analogue initiation to prevent carcinoid crisis. Patients undergoing any surgery with known or suspected GI NET must be evaluated by a NET specialist pre-operatively; octreotide must be available intra-operatively to prevent carcinoid crisis. New abdominal pain with imaging evidence of mesenteric fibrosis, small bowel obstruction, or a liver lesion in a patient with elevated CgA or 5-HIAA warrants urgent NET specialist referral. Patients with Type 1 or 2 gastric NETs require surveillance upper endoscopy every 1–2 years.